Camrelizumab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Resectable NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a multicenter, randomized, open-label, parallel controlled trial.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
This is a multicenter, randomized, open parallel controlled trial to evaluate the efficacy and safety of camrelizumab combined with albumin-bound paclitaxel and cisplatin versus albumin-bound paclitaxel combined with cisplatin in resectable stage IIIA -IIIB NSCLC (IIIB is limited toT3N2).
This is a multicenter, randomized, open parallel controlled trial to evaluate the efficacy and safety of camrelizumab combined with albumin-bound paclitaxel and cisplatin versus albumin-bound paclitaxel combined with cisplatin in resectable stage IIIA -IIIB NSCLC (IIIB is limited toT3N2).
Tracking Information
- NCT #
- NCT04338620
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jiang Tao, PhD The Fourth Military Medical University Tangdu Hospital
Get Well Soon